Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.

Scandinavian journal of gastroenterology - 1 Jul 2013

Lagging Martin, Rembeck Karolina, Rauning Buhl Mads, Christensen Peer, Dalgard Olav, Färkkilä Martti, Hellstrand Kristoffer, Langeland Nina, Lindh Magnus, Westin Johan, Norkrans Gunnar

Abstract excerpt

OBJECTIVES: Uncertainty remains regarding the efficacy of retreatment with current standard-of-care peg-interferon (peg-IFN) and ribavirin among patients infected with hepatitis C virus (HCV) genotypes 2 or 3 with relapse after prior therapy. MATERIALS AND METHODS: Seventy-one patients with chronic HCV genotype 2/3 with prior relapse were enrolled in a phase III multicenter study. Patients were retreated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 23795661
DOI: 10.3109/00365521.2013.793389

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.PMID 23795661Read ↗

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.Semantic proximity Read ↗

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?Semantic proximity Read ↗

Identifying HCV genotype 1 patients at risk of relapse.Semantic proximity Read ↗

Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.Semantic proximity Read ↗

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.Semantic proximity Read ↗

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.Semantic proximity Read ↗

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.Semantic proximity Read ↗

An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.Semantic proximity Read ↗

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.Semantic proximity Read ↗

Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.Semantic proximity Read ↗

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.